Investors and Partners
Trevena is backed by leading healthcare investors Alta Partners, HealthCare Ventures, New Enterprise Associates, Polaris Venture Partners and Yasuda Enterprise Development Company. Trevena has secured $60 million of venture financing to date. 
In November 2009, Trevena secured a $7.65 million NIH Grand Opportunity grant to expand its screening and chemistry efforts to six new GPCR targets.
Trevena also secured business financing administered by the Pennsylvania Department of Community and Economic Development (DCED) in November 2009, designed to stimulate the growth and assist in the retention of emerging and promising Pennsylvania businesses.
In May 2010, Trevena entered into a collaboration agreement with SCYNEXIS, under which Scynexis will provide medicinal chemistry services to expand lead optimization activities across Trevena’s growing portfolio of biased GPCR ligands.
Trevena has collaborated with Ligand Pharmaceuticals (NASDAQ: LGND) since early 2009 to screen GPCR targets against Ligand’s five million compound collection, to explore biased ligand hypotheses derived from Trevena’s ABLE™ platform. Screening activities will continue into the 3rd quarter of 2010, at which point Trevena will focus on progression of hits generated by this highly successful relationship.
